CHMP reversed its initial recommendation for the EC to not authorize the drug due to the risk of side effects like ARIA.

Eisai and Biogen have received marketing authorisation (MA) from the European Commission (EC) for Leqembi (lecanemab) to treat Alzheimer's disease. This authorisation makes the amyloid-beta (Aβ) ...

The EU approval comes after Eisai and Biogen were given approval for a new once-monthly intravenous maintenance dose of ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) wh ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild ...

These companies are showing how sustainability-focused businesses can drive lasting value. Powerhouse corporations secure rare energy deal that could reshape the grid: 'Decreases risk and increases ...

Nvidia Corp. Chief Executive Jensen Huang didn’t exactly please Wall Street at the so-called Super Bowl of AI. But now he’s giving President Donald Trump credit for his company’s new ...

Royalty Pharma (RPRX) announced the appointment of Vlad Coric to the company’s board of directors, effective immediately. Vlad Coric is the ...

Majority of chief executive officers (CEO) in the Philippines have a slightly optimistic outlook for the next 12 months. — PHILIPPINE STAR/RYAN BALDEMOR In the Ernst & Young (EY) CEO Outlook Survey, ...

Organon acquired regulatory and commercial rights in the United States for TOFIDENCE ™, a biosimilar to ACTEMRA ®, for intravenous infusion from Biogen. TOFIDENCE, the first approved ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...